The discrepancy in the number of subjects treated with remdesivir between two groups suggests that there might be imbalances in disease severity at baseline, which is supported by the observation that the symptom scores and plasma levels of IP-10 and MIG (COVID-19 disease progression markers as mentioned above) were lower in the placebo group. This evidence concerns the gene CXCL10 and COVID-19.